T-KNIFE

t-knife-logo

T-knife is a developer of T cell receptors intended for T cell therapy of cancer.The company uses a humanized TCR mice platform to carry human TCRαβ gene loci and recombine a broad repertoire of human TCRs, enabling the efficient generation and virtual selection of cell receptors for any human tumor antigen.

#SimilarOrganizations #People #Financial #Event #Website #More

T-KNIFE

Social Links:

Industry:
Biotechnology

Founded:
2018-01-01

Address:
Berlin, Berlin, Germany

Country:
Germany

Website Url:
http://www.t-knife.com

Total Employee:
51+

Status:
Active

Total Funding:
197.44 M USD

Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving Google Tag Manager Google Analytics Content Delivery Network Amazon Global Site Tag Google Analytics 4 Amazon Virginia Region


Similar Organizations

achilles-therapeutics-logo

Achilles Therapeutics

Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer.

bright-peak-therapeutics-logo

Bright Peak Therapeutics

Bright Peak is a biotech company that develops a portfolio of immunotherapies for the treatment of cancer and autoimmune diseases.

cyteir-therapeutics-logo

Cyteir Therapeutics

Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.

gracell-biotechnologies-logo

Gracell Biotechnologies

Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer.

immpact-bio-logo

ImmPACT Bio

ImmPACT Bio USA is developing novel cell therapies for treating cancer.

lava-therapeutics-logo

Lava Therapeutics

Lava Therapeutics is a developer of a bispecific antibody platform used to engage gamma-delta T cells for the treatment of cancer.

oxford-biomedica-logo

Oxford BioMedica

Oxford BioMedica is a pioneer of gene and cell therapy, with a leading industry position in lentiviral vector and cell therapy research.

rainier-therapeutics-logo

Rainier Therapeutics

Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.


Current Advisors List

not_available_image

Thomas Blankenstein Board Member @ T-knife
Board_member
2020-08-06

alexander-mayweg_image

Alexander Mayweg Board Member @ T-knife
Board_member
2020-08-06

olivier-litzka_image

Olivier Litzka Board Member @ T-knife
Board_member
2020-08-06

karin-kleinhans_image

Karin Kleinhans Board Member @ T-knife
Board_member
2021-08-01

frank-kalkbrenner_image

Frank Kalkbrenner Board Member @ T-knife
Board_member
2020-08-06

joshua-resnick_image

Joshua Resnick Board Member @ T-knife
Board_member
2020-08-06

Current Employees Featured

elisa-kieback_image

Elisa Kieback
Elisa Kieback CTO and co-founder @ T-knife
CTO and co-founder
2018-01-06

tom-soloway_image

Tom Soloway
Tom Soloway Chief Executive Officer @ T-knife
Chief Executive Officer
2020-12-01

camille-landis_image

Camille Landis
Camille Landis CBO / CFO @ T-knife
CBO / CFO
2021-02-01

simone-silva-steiner_image

Simone Silva Steiner
Simone Silva Steiner Chief Technical Operations Officer @ T-knife
Chief Technical Operations Officer

not_available_image

Thomas Blankenstein
Thomas Blankenstein Co-Founder @ T-knife
Co-Founder

Founder


elisa-kieback_image

Elisa Kieback

not_available_image

Thomas Blankenstein

Investors List

casdin-capital_image

Casdin Capital

Casdin Capital investment in Series B - T-knife

versant-ventures_image

Versant Ventures

Versant Ventures investment in Series B - T-knife

qatar-investment-authority_image

Qatar Investment Authority

Qatar Investment Authority investment in Series B - T-knife

edmond-de-rothschild-investment-partners_image

Andera Partners

Andera Partners investment in Series B - T-knife

ra-capital-management_image

RA Capital Management

RA Capital Management investment in Series B - T-knife

fidelity-investments_image

Fidelity

Fidelity investment in Series B - T-knife

caas-capital-management_image

CaaS Capital Management

CaaS Capital Management investment in Series B - T-knife

life-sciences-partners_image

EQT Life Sciences

EQT Life Sciences investment in Series B - T-knife

quantum-vista-capital_image

Sixty Degree Capital

Sixty Degree Capital investment in Series B - T-knife

edmond-de-rothschild-investment-partners_image

Andera Partners

Andera Partners investment in Series A - T-knife

Official Site Inspections

http://www.t-knife.com Semrush global rank: 4.79 M Semrush visits lastest month: 1.86 K

  • Host name: ec2-34-192-255-123.compute-1.amazonaws.com
  • IP address: 34.192.255.123
  • Location: Ashburn United States
  • Latitude: 39.0481
  • Longitude: -77.4728
  • Metro Code: 511
  • Timezone: America/New_York
  • Postal: 20149

Loading ...

More informations about "T-knife"

Management & Board of Directors | T-knife Therapeutics

About T-knife. T-knife Therapeutics is a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer. The company is initially focused on T cell receptor (TCR) …See details»

T-knife - Crunchbase Company Profile & Funding

T-knife is a developer of T cell receptors intended for T cell therapy of cancer.The company uses a humanized TCR mice platform to carry human TCRαβ gene loci and recombine a broad repertoire of human TCRs, enabling the efficient …See details»

Pipeline | TK-8001 | TK-2504 | Clinical Trials - T-knife

Why T-knife; Mission and Values; Job Opportunities; Contact; Pipeline. We are advancing a proprietary portfolio of TCR-T product candidates, for which we retain worldwide commercial rights. PRAME is found in cancers of the skin, …See details»

T-knife - Org Chart, Teams, Culture & Jobs | The Org

View T-knife's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»

T-Knife GmbH - Drug pipelines, Patents, Clinical trials - Synapse

Explore T-Knife GmbH with its drug pipeline, therapeutic area, technology platform, 2 clinical trials, 9 news, and 2 literature, Disease Domain:Neoplasms, Technology Platform:TCR …See details»

T-knife (T-Knife GmbH) - startbase.com

News about T-knife. Comprehensive Startup Listings: Startups from Berlin Startups from Berlin Startups from Germany. Recent mentions of T-knife in podcasts & videos: Jobs at T-knife: …See details»

T-knife - Contacts, Employees, Board Members, Advisors & Alumni

T-knife has 6 board members and advisors, including Thomas Blankenstein. Thomas Blankenstein Board Member Aug 6, 2020 Alexander Mayweg Board Member Aug 6, 2020See details»

T-Knife - EQT Group

Dec 2, 2024 T-knife is a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, initially focused on T cell receptor (TCR) Sector HealthcareSee details»

T-knife Company Profile - Office Locations, Competitors ... - Craft

T-knife has 5 employees at their 1 location and $110 m in total funding,. See insights on T-knife including office locations, competitors, revenue, financials, executives, subsidiaries and more …See details»

T-Knife Therapeutics Company Profile 2024: Valuation, …

Mar 14, 2018 T-Knife Therapeutics General Information Description. Developer of T cell receptor therapies designed to treat cancer. The company's therapies use a humanized TCR mice platform to carry human gene loci and recombine …See details»

T-knife - Funding, Financials, Valuation & Investors - Crunchbase

T-knife is a developer of T cell receptors intended for T cell therapy of cancer. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. Pricing. ...See details»

T-knife - Overview, News & Similar companies | ZoomInfo.com

Feb 8, 2023 T-knife contact info: Phone number: +49 3094892432 Website: www.t-knife.com What does T-knife do? Founded in 2018 and headquartered in Berlin, Germany, T-knife is a …See details»

T-KNIFE - VentureRadar

T-knife’s discovery engine has fueled a pipeline of TCR-T product candidates against solid tumor targets with high unmet medical need, including cancer testis antigens, oncoviral antigens and …See details»

Berlin start-up T-knife raises $110 million | Max Delbrück Center

Aug 2, 2021 T-knife’s lead program, TK-8001, is a novel TCR-T product candidate. It targets solid tumors that carry the antigen MAGE-A1 – a typical distinguishing feature on the surface …See details»

Press Release - T-knife

Jan 19, 2021 T-knife is backed by leading investors, including Versant Ventures, RA Capital, Andera Partners, and Boehringer Ingelheim Venture Fund. Contact. T-knife GmbH Camille …See details»

T-knife Therapeutics Announces $110 Million Series B

Aug 2, 2021 T-knife plans to begin enrolling patients in the TK-8001 IMAG1NE Phase 1/2 clinical study in the fourth quarter of 2021 and is planning to submit INDs/CTAs for additional product …See details»

T-knife Therapeutics Announces $110 Million Series B Financing to ...

Aug 2, 2021 T-knife plans to begin enrolling patients in the TK-8001 IMAG1NE Phase 1/2 clinical study in the fourth quarter of 2021 and is planning to submit INDs/CTAs for additional product …See details»

T-knife Therapeutics bags $110M to sharpen solid tumor cell …

Aug 2, 2021 T-knife will use the money to start enrolling patients with MAGE-A1 positive cancers in a phase 1/2 trial in the fourth quarter. Next year, T-knife plans to submit applications to run …See details»

Knife Maintenance 101: How to Care for Your Condor Knife to Last …

Nov 28, 2024 A typical knife consists of the blade, handle, tang, edge, and sometimes additional components like the guard or pommel. Each part requires proper care and …See details»

Knife River to acquire Strata for $454M - Nasdaq

1 day ago Knife River (KNF) announced that it has entered into a definitive agreement to acquire Strata. Based on Strata’s projected 2025 adjusted EBITDA, the purchase price of $454M …See details»

linkstock.net © 2022. All rights reserved